AZ's Imfinzi/tremelimumab combo misses again, this time in another NSCLC

AstraZeneca announced Wednesday that its Imfinzi durvalumab/tremelimumab combination failed to show a survival benefit in first-line non-small cell lung cancer. While the miss marks an end to AZ's recent spate of clinical successes, investors appeared undaunted by the miss, continuing to push the stock up to

Read the full 466 word article

User Sign In